BioInvent International Future Growth

Future criteria checks 6/6

BioInvent International is forecast to grow earnings and revenue by 62% and 55.6% per annum respectively. EPS is expected to grow by 53% per annum. Return on equity is forecast to be 45.6% in 3 years.

Key information

62.0%

Earnings growth rate

53.0%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	55.6%
Future return on equity	45.6%
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:BOVN.F - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	226	-72	N/A	N/A	2
12/31/2023	47	-312	N/A	N/A	2
12/31/2022	194	-109	N/A	N/A	2
6/30/2022	295	-42	-289	-276	N/A
3/31/2022	30	-266	-290	-276	N/A
12/31/2021	19	-278	-259	-246	N/A
9/30/2021	113	-171	-153	-141	N/A
6/30/2021	126	-141	-123	-115	N/A
3/31/2021	137	-123	-85	-78	N/A
12/31/2020	147	-76	-69	-63	N/A
9/30/2020	74	-146	-125	-119	N/A
6/30/2020	76	-150	-117	-112	N/A
3/31/2020	93	-144	-124	-120	N/A
12/31/2019	94	-139	-129	-125	N/A
9/30/2019	79	-130	-139	-136	N/A
6/30/2019	68	-116	-152	-148	N/A
3/31/2019	45	-126	-156	-152	N/A
12/31/2018	39	-123	-145	-141	N/A
9/30/2018	42	-124	-136	-126	N/A
6/30/2018	42	-123	-128	-116	N/A
3/31/2018	43	-103	-112	-99	N/A
12/31/2017	45	-101	-92	-76	N/A
9/30/2017	62	-75	-87	-76	N/A
6/30/2017	56	-82	-85	-75	N/A
3/31/2017	55	-85	-89	-81	N/A
12/31/2016	71	-63	-77	-72	N/A
9/30/2016	50	-76	-64	-59	N/A
6/30/2016	51	-70	-48	-46	N/A
3/31/2016	45	-69	N/A	-50	N/A
12/31/2015	16	-91	N/A	-73	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOVN.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: BOVN.F is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BOVN.F is expected to become profitable in the next 3 years.

Revenue vs Market: BOVN.F's revenue (55.6% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: BOVN.F's revenue (55.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BOVN.F's Return on Equity is forecast to be very high in 3 years time (45.6%).

BioInvent International Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Recent updates

BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma

Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024

BioInvent International Gains Patent for BI-1808 in China

BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024

Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL

BioInvent International AB (publ) to Report Nine Months, 2024 Results on Oct 31, 2024

BioInvent International AB (publ), Annual General Meeting, May 03, 2024

BioInvent International AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024

BioInvent International AB (publ) Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607

Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910

BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent

BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910

Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent International AB (publ) Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023

BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent Ready for Combination Studies with BT-001

BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs

BioInvent International AB (publ), Annual General Meeting, Apr 27, 2023

Bioinvent International AB Provides Update on Its Clinical and Pre-Clinical Pipeline, Including an Update on Its Lead Drug Candidate, the Novel Anti-Fc?RIIB Antibody Bi-1206

BioInvent International AB (publ) Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607

BioInvent International AB (publ) Completes Dose Escalation Part of the Phase I/IIa Study with Anti-TNFR2 Drug Candidate BI-1808

CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China

BioInvent International AB (publ) to Report Q2, 2023 Results on Aug 30, 2023

BioInvent International AB (publ) to Report Q1, 2023 Results on Apr 26, 2023

BioInvent International AB (publ) Enrolls First Patient in Phase 1/2A Trial of Bi-1607 in HER2 Positive Solid Tumors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies